The treatment of acute leukemia with continuous infusion L-Alanosine
- 1 September 1983
- journal article
- Published by Springer Nature in Investigational New Drugs
- Vol. 1 (3) , 249-252
- https://doi.org/10.1007/bf00208898
Abstract
L-Alanosine, an antitumor antibiotic was administered by members of the Southwest Oncology Group (SWOG) to 22 patients with resistant acute non-lymphocytic leukemia. The drug was administered by continuous infusion for five days at a starting dose of 125 mg/m2/day. Mucositis was dose-limiting in 15 patients and no marrow aplasia was attained. As administered, L-Alanosine is not an effective single agent in acute leukemia.Keywords
This publication has 4 references indexed in Scilit:
- Phase I study of L-alanosine (NSC 15353)Cancer, 1983
- Phase I study of L-alanosine using a daily x 3 schedule.1982
- ALANOSINE TOXICITY IN NOVIKOFF RAT HEPATOMA-CELLS DUE TO INHIBITION OF CONVERSION OF INOSINE MONOPHOSPHATE TO ADENOSINE-MONOPHOSPHATE1976
- Alanosine, a New Antiviral and Antitumour Agent isolated from a StreptomycesNature, 1966